- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S1401||Tenofovir||2 mg/mL||4 mg/mL||<1 mg/mL|
|S1400||Tenofovir Disoproxil Fumarate||<1 mg/mL||100 mg/mL||44 mg/mL|
|S1704||Emtricitabine||49 mg/mL||49 mg/mL||9 mg/mL|
|S1252||Entecavir Hydrate||<1 mg/mL||59 mg/mL||<1 mg/mL|
|S1718||Adefovir Dipivoxil||<1 mg/mL||100 mg/mL||100 mg/mL|
|S3606||Fangchinoline||<1 mg/mL||100 mg/mL||4 mg/mL|
|S1742||Nevirapine||<1 mg/mL||53 mg/mL||<1 mg/mL|
|S1702||Didanosine||<1 mg/mL||47 mg/mL||<1 mg/mL|
|S1706||Lamivudine||46 mg/mL||46 mg/mL||<1 mg/mL|
|S1398||Stavudine (d4T)||<1 mg/mL||45 mg/mL||15 mg/mL|
|S1651||Telbivudine||48 mg/mL||48 mg/mL||2 mg/mL|
|S3080||Etravirine (TMC125)||<1 mg/mL||42 mg/mL||<1 mg/mL|
|S2579||Zidovudine||53 mg/mL||53 mg/mL||18 mg/mL|
|S1719||Zalcitabine||42 mg/mL||7 mg/mL||<1 mg/mL|
|S3165||Abacavir sulfate||36 mg/mL||<1 mg/mL||<1 mg/mL|
|S2914||Dapivirine (TMC120)||<1 mg/mL||34 mg/mL||<1 mg/mL|
|S3076||Foscarnet Sodium||3 mg/mL||7 mg/mL||<1 mg/mL|
|S7303||Rilpivirine||<1 mg/mL||73 mg/mL||<1 mg/mL|
|S4187||Salicylanilide||<1 mg/mL||43 mg/mL||18 mg/mL|
|S4685||Efavirenz||<1 mg/mL||63 mg/mL||63 mg/mL|
|S7856||Tenofovir Alafenamide (GS-7340)||<1 mg/mL||95 mg/mL||95 mg/mL|
- Reverse Transcriptase Inhibitors (21)
- New Reverse Transcriptase Products
|Catalog No.||Information||Product Use Citations||Product Validations|
Tenofovir blocks reverse transcriptase and hepatitis B virus infections.
The Nucleotide analog reverse-transcriptase inhibitor Tenofovir disoproxil fumarate was added to TZM-bl cells. Cells were inoculated with 0.05 ng mock-exposed and semen-exposed HIV, and 0.5 ng HIV as infectivity-matched control. Infection rates were measured 3 days post infection by measuring β-galactosidase or or 4 days post infection by measuring luciferase activities. The left panels show the mean enzyme activities ± standard deviation derived from triplicate infections. RLU/s: relative light units per second. Middle panels show normalized infection rates in which reporter enzyme activities obtained from infected cells in the absence of inhibitor were set at 100%. The right panels depict the calculated IC50 values. The number above the bar represents the fold-change in the IC50 derived from 0.05 ng semen-exposed relative to 0.05 or 0.5 ng mock-exposed virus infection. Ns, no statistically significant difference; **** p<0.0001; *** p<0.001 (unpaired t-test).
Tenofovir Disoproxil Fumarate belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination.
Human PBMCs containing indicated concentrations of Tenofovir disoproxil fumarate were inoculated with 5 ng mock-exposed or semen-exposed R5-HIV-luciferase, or 50 ng R5-HIV-luciferase as infectivity matched control. Infection rates were determined 3 days post inoculation.
Emtricitabine (FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
Entecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).
Adefovir Dipivoxil is a reverse transcriptase inhibitor, used in the treatment of chronic hepatitis B virus (HBV).
Fangchinoline, a bisbenzylisoquinoline alkaloid, is a novel HIV-1 inhibitor with pain-relieving, blood pressure-depressing, and antibiotic activities.
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS.
Cells were inoculated with 0.05 ng mock-exposed and semen-exposed HIV, and 0.5 ng HIV as infectivity-matched control. Infection rates were measured 3 d post infection by measuring β-galactosidase. Left: the mean enzyme activities. Middle: normalized infection rates in which reporter enzyme activities obtained from infected cells in the absence of nevirapine were set at 100%. Right: IC50 values.
Didanosine is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor, used for treatment of chronic HBV and HIV/AIDS. It works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase.
The indicated liver cancer cell lines—Hep-3B, Huh-7 and PLC were treated with or without 5 types anti-hepatitis B virus drugs (C) with the concentration of 100 μM, and M1 virus (MOI = 10) for 72 hours. Following 72 hours, cell viabilities were determined by MTT assay (mean ± SD). N.S. Not significant.
Stavudine (d4T) is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.
Telbivudine is a potent, and selective HBV reverse transcriptase inhibitor, used to treat HBV infection.
Etravirine (TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.
Zidovudine (ZDV) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV.
Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI).
Abacavir is a commonly used nucleoside analogue with potent antiviral activity against HIV-1.
Dapivirine (TMC120) is a non-nucleoside inhibitor for HIV reverse transcriptase with IC50 of 24 nM, inhibits a broad panel of HIV-1 isolates from different classes, inclucing a wide range of NNRTI-resistant isolates. Phase 3.
Foscarnet Sodium inhibits viral RNA polymerases, reverse transcriptase, and DNA polymerases through noncompetitive inhibition with dNTPs.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), and used to treat HIV-1 infection.
Salicylanilides are a group of compounds with a wide range of biological activities including antiviral potency, antibacterial (including antimycobacterial) and antifungal activities.
Efavirenz is a synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity.
Tenofovir Alafenamide (GS-7340) is a prodrug of tenofovir, which is a reverse transcriptase inhibitor, used to treat HIV and Hepatitis B.